Condition: Psychosis Associated With Alzheimer's Disease · Sponsor: MapLight Therapeutics
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
This description comes directly from the study's public registry record.
Clinical Trials Contact Center · +1 650 839 4380 · ML-007C-MA-ADP@maplightrx.com
Always discuss trial participation with your own doctor first.
| Clinical Site | Phoenix, Arizona, United States | Recruiting |
| Clinical Site | Scottsdale, Arizona, United States | Recruiting |
| Clinical Site | Tucson, Arizona, United States | Recruiting |
| Clinical Site | Anaheim, California, United States | Recruiting |
| Clinical Site | Orange, California, United States | Recruiting |
| Clinical Site | San Diego, California, United States | Recruiting |
| Clinical Site | Boca Raton, Florida, United States | Recruiting |
| Clinical Site | Deerfield Beach, Florida, United States | Recruiting |
| Clinical Site | Doral, Florida, United States | Recruiting |
| Clinical Site | Homestead, Florida, United States | Recruiting |
| Clinical Site | Miami, Florida, United States | Recruiting |
| Clinical Site | Miami, Florida, United States | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06887192